News

SELLAS Life Sciences (SLS) stock gains as a Phase 2 trial for its cancer drug SLS009 succeds in patients with acute myeloid ...
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg ...
Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.
The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing ...
The FDA has accepted the supplemental new drug application for decitabine/cedazuridine plus venetoclax to treat adults with AML.
A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...
A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.
At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.
Venetoclax shows potential in pediatric relapsed/refractory AML/MDS, with a 41.6% overall response rate and 33% complete response rate in a single-center study.
Ibrutinib plus venetoclax demonstrated superior PFS and a higher complete response rate compared with ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma, according ...
The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.